X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (33) 33
humans (30) 30
melanoma (28) 28
oncology (22) 22
female (21) 21
male (20) 20
aged (18) 18
melanoma - drug therapy (18) 18
middle aged (17) 17
adult (16) 16
metastasis (16) 16
aged, 80 and over (14) 14
hematology, oncology and palliative medicine (13) 13
immunotherapy (13) 13
ipilimumab (13) 13
skin neoplasms - drug therapy (13) 13
survival (13) 13
care and treatment (12) 12
clinical trials (12) 12
skin neoplasms - pathology (12) 12
studies (12) 12
cancer (10) 10
mutation (10) 10
treatment outcome (10) 10
analysis (9) 9
disease-free survival (8) 8
neoplasm staging (8) 8
adolescent (7) 7
cutaneous melanoma (7) 7
dermatology (7) 7
drug dosages (7) 7
life sciences (7) 7
medical colleges (7) 7
melanoma - secondary (7) 7
metastases (7) 7
nivolumab (7) 7
patients (7) 7
prognosis (7) 7
risk factors (7) 7
young adult (7) 7
antineoplastic agents - adverse effects (6) 6
antineoplastic agents - therapeutic use (6) 6
double-blind method (6) 6
follow-up studies (6) 6
melanoma - pathology (6) 6
retrospective studies (6) 6
surgery (6) 6
tumors (6) 6
abridged index medicus (5) 5
antibodies, monoclonal - adverse effects (5) 5
chemotherapy (5) 5
disease progression (5) 5
immune checkpoint (5) 5
medical prognosis (5) 5
medicine, research & experimental (5) 5
melanoma - genetics (5) 5
melanoma - mortality (5) 5
pembrolizumab (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
quality of life (5) 5
research (5) 5
skin cancer (5) 5
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
braf (4) 4
cancer therapies (4) 4
drug therapy (4) 4
human health and pathology (4) 4
kinases (4) 4
lymphatic system (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
melanoma - surgery (4) 4
metastatic melanoma (4) 4
pd-1 protein (4) 4
proto-oncogene proteins b-raf - antagonists & inhibitors (4) 4
safety (4) 4
skin neoplasms - mortality (4) 4
time factors (4) 4
toxicity (4) 4
usage (4) 4
vemurafenib (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antigens (3) 3
antineoplastic agents - administration & dosage (3) 3
article (3) 3
basal cell carcinoma (3) 3
carcinoma, basal cell - drug therapy (3) 3
carcinoma, basal cell - pathology (3) 3
case-control studies (3) 3
cohort studies (3) 3
comparative analysis (3) 3
diagnosis, differential (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
expression (3) 3
gene mutations (3) 3
imidazoles - administration & dosage (3) 3
immune system (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal Article
Journal Article